MedWatch

CHMP recommends Novo Nordisk's Saxenda for adolescents

The EU Committee for Medicinal Products for Human Use (CHMP) which recommends drugs for approval in Europe, vouches for an expanded indication of Novo Nordisk's obesity drug Saxenda, so it can be used for adolescents aged 12-17 years.

Photo: Stine Tidsvilde

European health authorities recommend an extended use of Novo Nordisk's weight loss drug Saxenda so that it may also be used for treating obesity in children and adolescents aged 12-17, according to a Novo Nordisk press release.

If the EU Commission gives the necessary marketing authorization for this patient group, Sazenda will be the first weight loss drug to be approved for youngsters in Europe.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Further reading

Related articles

Latest news

See all jobs